title: Development of Proteasome Inhibitors as Therapeutic Drugs.
abstract: The proteasome is a multi-unit enzyme complex found in the cytoplasm and nucleus of all eukaryotic cells and is responsible for degradation of unneeded or damaged intracellular proteins by proteolysis, a chemical reaction that breaks peptide bonds. Proteasome inhibition presents a promising approach to cancer therapy by targeting the proteasome function in tumor cells. Delineating the success of bortezomib in the treatment of multiple myeloma and mantle cell lymphoma, this review explores various proteasome inhibitors, currently in development, as molecular targeting agents in the fight against cancer. Proteasome inhibitors can be used alone or in combination with other conventional cancer therapies to sensitize tumor cells to cell death by various mechanisms and improve therapeutic benefits.
authors: Laboratory of Lymphocyte Function, Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN 37208, USA ; School of Graduate Studies and Research, Meharry Medical College, Nashville, TN 37208, USA ; Department of Microbiology and Immunology, School of Medicine, Meharry Medical College, Nashville, TN 37208, USA.
authors: Samuel Troy
authors: ST
authors: Pellom
authors: Anil
authors: A
authors: Shanker